君实生物拓益新增4项适应症纳入医保目录
财中社11月28日电君实生物（688180/01877）发布自愿披露公告，宣布其产品特瑞普利单抗注射液（拓益®）新增4项适应症成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》的乙类范围。此次新增适应症将于2025年1月1日起正式实施，拓益®在中国内地已获批的10项适应症全部纳入国家医保目录，成为唯一用于黑色素瘤、非小细胞肺癌围手术期、肾癌和三阴性乳腺癌治疗的抗PD-1单抗。
新增的适应症包括与化疗联合用于不可切除或转移性肾细胞癌、复发/转移性鼻咽癌等的治疗。这次医保目录的更新反映了国家医保局对该药物临床价值的认可，预计将拓宽患者获益范围，减轻就医负担，并为公司在相关适应症市场推广上提供先发优势，有助于提升药物的市场可及性和销售规模，对公司的长期经营发展产生积极影响。
2024年前三季度，君实生物-U实现收入12.71亿元，归母净利润-9.27亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10